Home › Calculator › AAPG Dividend Calculator 2026
AAPG Dividend DRIP Calculator 2026
10.60% YieldHealthcareAscentage Pharma Group International · NASDAQ
Price: $18.86 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When AAPG pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your AAPG snowball 📈
$10,000 in AAPG → $11.36M in 10 years · $98.06/month
About Ascentage Pharma Group International (AAPG) — Dividend Analysis 2026
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.
Compare AAPG with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full AAPG DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open AAPG position with:
🌍 AAPG Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold AAPG.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 10.60% | 7.80% | $1,060 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 9.01% | 6.21% | $901 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 8.48% | 5.68% | $848 / yr |
| 🇬🇧 UK ISA | 0% | 10.60% | 7.80% | $1,060 / yr |
| 🇬🇧 UK Taxable | 8.75% | 9.67% | 6.87% | $967 / yr |
| 🇨🇦 TFSA | 0% | 10.60% | 7.80% | $1,060 / yr |
| 🇨🇦 CA Taxable | 25% | 7.95% | 5.15% | $795 / yr |
| 🇦🇺 Super (pension) | 15% | 9.01% | 6.21% | $901 / yr |
| 🇦🇺 AU Taxable | 30% | 7.42% | 4.62% | $742 / yr |
| 🇩🇪 DE Taxable | 26.375% | 7.80% | 5.00% | $780 / yr |
| 🇫🇷 FR Taxable | 30% | 7.42% | 4.62% | $742 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 AAPG Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 AAPG Dividend Payment Schedule
AAPG pays quarterly — 4 times per year. Next ex-div: TBD.
📊 AAPG vs Healthcare Benchmarks
How AAPG compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for AAPG sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ AAPG Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| M-Exempt | 2026-05-21 | 95,575 | — | — | ||
| M-Exempt | 2026-05-21 | 92,746 | — | — | ||
| A-Award | 2026-05-20 | 298,195 | — | — | ||
| A-Award | 2026-05-20 | 298,194 | $6.58 | $1.96M | ||
| A-Award | 2026-05-20 | 214,999 | — | — | ||
| A-Award | 2026-05-20 | 214,988 | $6.58 | $1.41M | ||
| A-Award | 2026-05-20 | 103,365 | — | — | ||
| A-Award | 2026-05-20 | 103,364 | $8.12 | $839.3K | ||
| A-Award | 2026-05-20 | 95,575 | — | — | ||
| A-Award | 2026-05-20 | 92,746 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the AAPG dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Ascentage Pharma Group International (AAPG) is currently trading at $18.86, 55% below its 52-week high. The current dividend yield is 10.60% based on an annual payout of $2.00 per share.
AAPG (Ascentage Pharma Group International) — 10.60% Dividend Yield Analysis
Ascentage Pharma Group International (AAPG) is a healthcare stock currently trading at $18.86 with a dividend yield of 10.60%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (10.60%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.